Cara Therapeutics price target lowered to $25 from $29 at Canaccord

Canaccord analyst Sumant Kulkarni lowered the firm’s price target on Cara Therapeutics to $25 from $29 and keeps a Buy rating on the shares. The analyst sees the recent pullback presenting a particularly compelling entry point for risk-tolerant investors to own an oral Korsuva-driven story on which we will start seeing more data as we get into the later part of 2023.